Evidence map›Paper›PMID 29492198›Full record

ArticleOncotarget2018

UBASH3B promotes tamoxifen resistance and could be negatively regulated by ESR1.

Ketao Jin, Huanrong Lan, Junyu Zhang, Jieqing Lv, Yuan Chen, Kang Yu, Wei Wang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. A NJournal of oncology · 2022
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Ketao JinDepartment of Colorectal Surgery, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, 312000, Zhejiang Province, P.R. China.
Huanrong LanDepartment of Breast and Thyroid Surgery, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, 312000, Zhejiang Province, P.R. China.
Junyu ZhangDepartment of Hematology, The Fifth Affiliated Hospital of Wenzhou Medical School, Lishui, 323000, Zhejiang Province, P.R. China.
Jieqing LvDepartment of Colorectal Surgery, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, 312000, Zhejiang Province, P.R. China.
Yuan ChenDepartment of Pathology, Zhejiang Provincial People's Hospital, Hangzhou, 310014, Zhejiang Province, P.R. China.
Kang YuDepartment of Hematology, The First Affiliated Hospital of Wenzhou Medical School, Wenzhou, 323000, Zhejiang Province, P.R. China.
Wei WangDepartment of Pathology, Zhejiang Provincial People's Hospital, Hangzhou, 310014, Zhejiang Province, P.R. China.
Shaoxing People's Hospital · CNZhejiang Provincial People's Hospital · CNWenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo explore the prognostic value of UBASH3B in ER+ breast cancer patients and explore potential molecular mechanisms. MATERIALS AND

methodsDatasets from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were re-analyzed to explore the association between UBASH3B and the progression of ER+ breast cancer. Kaplan-Meier plot analysis with a total of 734 ER+ samples and Gene Set Enrichment Analysis with 632 samples were used in the study.

resultsHigh expression of UBASH3B is negatively correlated with distant metastasis free survival (DMFS,

conclusionsUBASH3B is negatively regulated by ER and confers poor outcome in ER+ breast cancer patients. Cisplatin is a potential therapeutic option for the management of breast cancer patients with high expression of UBASH3B.

Indexed as

breast cancerprognosistamoxifen resistanceTP53 mutationUBASH3B

Identifiers

PMID29492198
PMCPMC5823602
OpenAlexW2776932032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.